TNFRSF17 and plasma cell myeloma: Currently, different classes of myeloma therapies exist, including steroids, alkylators, proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), selective inhibitors of nuclear export, monoclonal antibodies, and B-cell maturation antigen (BCMA)-targeted therapies; these agents are often used in combination for myeloma management [3].